Format

Send to

Choose Destination
Autoimmun Rev. 2016 Nov;15(11):1054-1061. doi: 10.1016/j.autrev.2016.07.030. Epub 2016 Aug 1.

From HBV to HPV: Designing vaccines for extensive and intensive vaccination campaigns worldwide.

Author information

1
Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari 70126, Italy. Electronic address: darja.kanduc@uniba.it.
2
Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 5265601, Israel.

Abstract

HBsAg and HPV L1 proteins - the HBV and HPV antigens utilized in current vaccines - share amino acid sequences with human proteins such as cardiomyopathy-associated protein 5, titin, protein-arginine deiminase, E3 ubiquitin-protein ligase RNF19A, bassoon, G-protein coupled receptor for fatty acids, insulin isoform 2, and mitogen-activated protein kinase kinase kinase 10, inter alia. Many shared peptides are also part of immunopositive epitopes. The data 1) support the possibility of crossreactions between the two viral antigens and human proteins that, when altered, may associate with neuropsychiatric, cardiovascular and metabolic diseases such as multiple sclerosis, amyotrophic lateral sclerosis, diabetes, and sudden death; 2) confirm the concept that only vaccines based on sequences unique to pathogens might nullify potential crossreactivity risks in vaccination protocols.

KEYWORDS:

Autoimmune reactions; HBV/HPV vaccines; Peptide crossreactivity; Peptide uniqueness concept; Safe and effective vaccines

PMID:
27490205
DOI:
10.1016/j.autrev.2016.07.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center